Trials / Not Yet Recruiting
Not Yet RecruitingNCT07102056
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (estimated)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-AlF-NOTA-Octreotide PET-CT or PET-MR | 18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-06-03
- Completion
- 2027-12-31
- First posted
- 2025-08-03
- Last updated
- 2025-12-29
Source: ClinicalTrials.gov record NCT07102056. Inclusion in this directory is not an endorsement.